RLS-0071

Phase 2Small molecule

RReAlta Life Sciences, Inc.

RLS-0071 is one of 122 small molecule programs targeting Respiratory Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

EncephalopathyActive, not recruiting

COVID-19Active, not recruiting

Respiratory FailurePhase 1

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

RLS-0071

RReAlta Life Sciences, Inc.

Phase 2

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—4

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 5

COVID-19 Vaccines

UUniversity of British Columbia

Preclinical

10 6

Other Tkis

Bayer

Preclinical

1 7

Pfizer-COVID-19 Vaccine

Moderna

Preclinical

1 8

Netakimab

SSPH-BIOCAD (HK) Limited

Preclinical

1 9

Saliva Collection

DDirection Centrale du Service de Santé des Armées

Preclinical

4 10

Mrna-1273.211

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Steroid-Refractory Acute Graft-Versus-Host Disease

NCT06343792

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Active, not recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT06175065·24 enrolled

Respiratory Failure1 trial

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

Withdrawn·RReAlta Life Sciences, Inc.·Phase 1·NCT04574869

COVID-191 trial

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

Completed·RReAlta Life Sciences, Inc.·Phase 1·NCT05298787·56 enrolled

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT06343792·66 enrolled

Encephalopathy1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT05778188·42 enrolled

1 more indication

Adult1 trial

A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS

Completed·RReAlta Life Sciences, Inc.·Phase 1·NCT05351671·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for RLS-0071. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RLS-0071 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RLS-0071. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ReAlta Life Sciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RReAlta Life Sciences, Inc.

RLS-0071

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Respiratory Failure1 trial

COVID-191 trial

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Encephalopathy1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News